lanreotide (Autogel formulation)

DRUG13 trials

Sponsors

Ipsen

Conditions

AcromegalyDiarrheaEndocrine TumorsIntestinal ObstructionNeuroendocrine Tumors in LungNeuroendocrine Tumour With Carcinoid SymptomsNeuroendocrine TumoursNon Functioning Entero-pancreatic Endocrine Tumour

Phase 2

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

CompletedNCT00234572

IpsenAcromegaly

Start: 2000-05-31End: 2003-01-03Updated: 2019-08-02

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

CompletedNCT00326469

IpsenNeuroendocrine Tumours

Start: 2006-05-31End: 2009-11-30Updated: 2020-11-05

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

WithdrawnNCT00517491

IpsenAcromegaly

Start: 2008-05-31End: 2008-12-31Updated: 2019-08-05

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

CompletedNCT00891371

Start: 2009-07-31End: 2013-08-31Updated: 2019-01-15

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

TerminatedNCT02365584

IpsenIntestinal Obstruction

Start: 2015-01-31End: 2018-01-16Updated: 2019-11-22

Phase 3

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

CompletedNCT00210457

IpsenAcromegaly

Start: 2000-09-30End: 2002-07-15Updated: 2020-03-31

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

CompletedNCT00353496

IpsenEndocrine Tumors

Start: 2006-06-30End: 2013-04-30Updated: 2025-03-05

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

CompletedNCT00383708

IpsenAcromegaly

Start: 2006-10-31End: 2008-10-31Updated: 2022-09-27

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

CompletedNCT00842348

IpsenNon Functioning Entero-pancreatic Endocrine Tumour

Start: 2009-02-28End: 2015-12-31Updated: 2022-10-12

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

TerminatedNCT02683941

IpsenNeuroendocrine Tumors in Lung

Start: 2017-03-06End: 2020-02-28Updated: 2022-07-06

Phase 4

Somatuline Autogel: Acromegaly Self/Partner Injection Study

CompletedNCT00149188

IpsenAcromegaly

Start: 2004-02-29End: 2005-08-24Updated: 2019-08-05

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

CompletedNCT00216398

IpsenAcromegaly

Start: 2004-06-30End: 2006-06-22Updated: 2019-08-16

Somatuline Autogel Preference and Health Economy Study

CompletedNCT00681187

IpsenNeuroendocrine Tumour With Carcinoid Symptoms

Start: 2008-06-30End: 2010-08-31Updated: 2019-11-22

Related Papers

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study

Endocrine Related Cancer2024-06-2423 citations

The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

Future Oncology2023-07-275 citations

Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors

Future Oncology2023-07-275 citations

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.

2020-10-1459 citations

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

Anti-Cancer Drugs2020-01-248 citations

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

BMC Cancer2019-01-1467 citations

Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)

Annals of Oncology2018-10-011 citations

Tumor growth and regression rate constants from the CLARINET study as surrogate endpoints for progression free survival: A novel assessment approach in cancer therapy.

Journal of Clinical Oncology2018-05-20

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: <scp>RADIANT</scp>‐4 lung subgroup analysis

Cancer Science2017-10-2197 citations

Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.

Journal of Clinical Oncology2017-05-2016 citations

Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study.

Journal of Clinical Oncology2017-05-203 citations

Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies.

Journal of Clinical Oncology2017-02-01

Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.

2016-08-0811 citations

Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study.

Journal of Clinical Oncology2016-05-206 citations

Safety and efficacy of lanreotide depot/autogel (LAN) in patients with lung NETs: The randomized, double-blind, placebo (PBO)-controlled phase III SPINET study.

Journal of Clinical Oncology2016-05-205 citations

Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Journal of Clinical Oncology2016-02-0113 citations

Antitumor Activity of Lanreotide Autogel 120 mg in Enteropancreatic Neuroendocrine Tumour (NET) Patients: The Clarinet Open-Label Extension Study

Zeitschrift für Gastroenterologie2015-08-18

Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.

Journal of Clinical Oncology2015-05-204 citations

Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).

Journal of Clinical Oncology2015-05-203 citations

Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.

Journal of Clinical Oncology2015-05-203 citations

10 more papers not shown